Insufficient bilateral femoral subtrochanteric fractures in a patient receiving imatinib mesylate

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 6, 2010, Pages 713-718

  Yang, Kyu Hyun ^a   Park, Si Young ^b   Park, Sang Won ^b   Lee, Soon Hyuck ^b   Han, Seung Beom ^b   Jung, Woong Kyo ^b   Kim, Suk Jin ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

Author keywords

Bone turnover; Femur; Imanitib mesylate; Insufficient fracture

Indexed keywords

25 HYDROXYVITAMIN D; AMINO TERMINAL TELOPEPTIDE; ANALGESIC AGENT; CALCIUM; IMATINIB; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; THYROID HORMONE; VITAMIN D DERIVATIVE;

ADULT; ARTICLE; BONE BIOPSY; BONE DENSITOMETRY; BONE MINERALIZATION; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALLUS; CANCER CHEMOTHERAPY; CANCER CONTROL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DISEASE DURATION; DRUG EFFECT; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; FRACTURE NONUNION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRAMEDULLARY NAILING; LEG PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SECONDARY HYPERPARATHYROIDISM; STRESS FRACTURE; TREATMENT DURATION; VITAMIN BLOOD LEVEL; WHOLE BODY CT;

ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE REMODELING; FEMALE; FEMORAL FRACTURES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOPHOSPHATEMIA; LEUKEMIA, MYELOID, CHRONIC-PHASE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES;

EID: 78349231233     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-010-0203-2     Document Type: Article

References (24)

1. DG Savage KH Antman 2002 Imatinib mesylate: a new oral targeted therapy N Engl J Med 346 683 693 1:CAS:528:DC%2BD38XhsFOjsro%3D 10.1056/NEJMra013339 11870247
2. BJ Druker 2004 Imatinib as a paradigm of targeted therapies Adv Cancer Res 91 1 30 1:CAS:528:DC%2BD2cXhtVent7bP 10.1016/S0065-230X(04)91001-9 15327887
3. BJ Druker M Talpaz DJ Resta B Peng E Buchdunger JM Ford NB Lydon H Kantarjian R Capdeville S Ohno-Jones CL Sawyers 2001 Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med 344 1031 1037 1:CAS:528:DC%2BD3MXivFGnu70%3D 10.1056/ NEJM200104053441401 11287972
4. E Berman M Nicolaides RG Maki M Fleisher S Chanel K Scheu BA Wilson G Heller NP Sauter 2006 Altered bone and mineral metabolism in patients receiving imatinib mesylate N Engl J Med 354 2006 2013 1:CAS:528:DC%2BD28XksFGhs7s%3D 10.1056/NEJMoa051140 16687713
5. A Grey S O'Sullivan IR Reid P Browett 2006 Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism N Engl J Med 355 2494 2495 1:CAS:528:DC%2BD28Xht12ntb%2FF 10.1056/NEJMc062388 17151376
6. JE Zerwekh PP Antich K Sakhaee J Prior J Gonzales F Gottschalk CY Pak 1992 Lack of deleterious effect of slow-release sodium fluoride treatment on cortical bone histology and quality in osteoporotic patients Bone Miner 18 65 76 1:STN:280:DyaK3s%2FksVOkuw%3D%3D 10.1016/0169-6009(92)90800-S 1422299
7. RR Recker DB Kimmel AM Parfitt KM Davies N Keshawarz S Hinders 1988 Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females J Bone Miner Res 3 133 144 1:STN:280:DyaL1M7gt1KrtA%3D%3D 10.1002/jbmr.5650030203 3213608
8. JD Coe WA Murphy MP Whyte 1986 Management of femoral fractures and pseudofractures in adult hypophosphatasia J Bone Joint Surg Am 68 981 990 1:STN:280:DyaL28zgsVGgsA%3D%3D 3745261
9. MP Somford FW Draijer BJ Thomassen PM Chavassieux G Boivin SE Papapoulos 2009 Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility J Bone Miner Res 24 1736 1740 10.1359/jbmr.090408 19419297
10. LE Targownik LM Lix CJ Metge HJ Prior S Leung WD Leslie 2008 Use of proton pump inhibitors and risk of osteoporosis-related fractures Can Med Assoc J 179 319 326 10.1503/cmaj.071330
11. JA Kanis H Johansson A Oden O Johnell C de Laet IL Melton A Tenenhouse J Reeve AJ Silman HA Pols JA Eisman EV McCloskey D Mellstrom 2004 A meta-analysis of prior corticosteroid use and fracture risk J Bone Miner Res 19 893 899 10.1359/JBMR.040134 15125788
12. CV Odvina JE Zerwekh DS Rao N Maalouf FA Gottschalk CY Pak 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy J Clin Endocrinol Metab 90 1294 1301 1:CAS:528:DC%2BD2MXisVOhsr0%3D 10.1210/jc.2004-0952 15598694
13. T Mashiba T Hirano CH Turner MR Forwood CC Johnston DB Burr 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib J Bone Miner Res 15 613 620 1:CAS:528:DC%2BD3cXisFWmtr4%3D 10.1359/jbmr.2000.15.4.613 10780852
14. RD Chapurlat M Arlot B Burt-Pichat P Chavassieux JP Roux N Portero-Muzy PD Delmas 2007 Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study J Bone Miner Res 22 1502 1509 1:CAS:528:DC%2BD2sXhtFyhu7nJ 10.1359/jbmr.070609 17824840
15. M Breccia G Alimena 2009 The metabolic consequences of imatinib mesylate: changes on glucose, lypidic and bone metabolism Leuk Res 33 871 875 1:CAS:528:DC%2BD1MXlsVGquro%3D 10.1016/j.leukres.2009.01.040 19307018
16. AL Dewar AN Farrugia MR Condina L Bik To TP Hughes B Vernon-Roberts AC Zannettino 2006 Imatinib as a potential antiresorptive therapy for bone disease Blood 107 4334 4337 1:CAS:528:DC%2BD28Xlt1CgsLo%3D 10.1182/blood-2005-09-3568 16449525
17. SL Teitelbaum 2000 Bone resorption by osteoclasts Science 289 1504 1508 1:CAS:528:DC%2BD3cXmt1KgsLk%3D 10.1126/science.289.5484.1504 10968780
18. W Wiktor-Jedrzejczak A Bartocci AW Ferrante Jr A Ahmed-Ansari KW Sell JW Pollard ER Stanley 1990 Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse Proc Natl Acad Sci USA 87 4828 4832 1:CAS:528:DyaK3cXksFOhsbg%3D 10.1073/pnas.87.12.4828 2191302
19. AC Looker DC Bauer CH Chesnut 3rd CM Gundberg MC Hochberg G Klee M Kleerekoper NB Watts NH Bell 2000 Clinical use of biochemical markers of bone remodeling: current status and future directions Osteoporos Int 11 467 480 1:STN:280:DC%2BD3cvotFSitA%3D%3D 10.1007/s001980070088 10982161
20. MT Rehman JA Hoyland J Denton AJ Freemont 1994 Age related histomorphometric changes in bone in normal British men and women J Clin Pathol 47 529 534 1:STN:280:DyaK2czkt1Gjsw%3D%3D 10.1136/jcp.47.6.529 8063935
21. PM Chavassieux ME Arlot C Reda L Wei AJ Yates PJ Meunier 1997 Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis J Clin Invest 100 1475 1480 1:CAS:528:DyaK2sXmt1Cqsb8%3D 10.1172/JCI119668 9294113
22. SK Goh KY Yang JS Koh MK Wong SY Chua DT Chua TS Howe 2007 Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution J Bone Joint Surg Br 89 349 353 10.1302/0301-620X.89B3.18146 17356148
23. CM Capeci NC Tejwani 2009 Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy J Bone Joint Surg Am 91 2556 2561 10.2106/JBJS.H.01774 19884427
24. FH Glorieux R Travers A Taylor JR Bowen F Rauch M Norman AM Parfitt 2000 Normative data for iliac bone histomorphometry in growing children Bone (NY) 26 103 109 1:STN:280:DC%2BD3c7ktFyksw%3D%3D